AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Vor Biopharma Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Reprogrammed Interchange LLC, an entity associated with Reid Hoffman, reported sales of common stock of Vor Biopharma Inc. (VOR) on August 25-26, 2025. The filing shows 387,346 shares sold on 08/25/2025 at a weighted average price of $2.1163, and 284,190 shares sold on 08/26/2025 at a weighted average price of $2.0808. Following the 08/25 sale the filing reports 38,586,755 shares beneficially owned by Reprogrammed and after the 08/26 sale 38,302,565 shares were reported.

The filer states the shares are held by Reprogrammed Interchange LLC and that Reid Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest, while disclaiming beneficial ownership except to the extent of his pecuniary interest. The transactions were signed on 08/27/2025 by Frank Huang, Manager of Reprogrammed Interchange LLC, and Reid Hoffman.

Reprogrammed Interchange LLC, entità collegata a Reid Hoffman, ha comunicato la vendita di azioni ordinarie di Vor Biopharma Inc. (VOR) nei giorni 25-26 agosto 2025. La comunicazione indica la vendita di 387.346 azioni il 25/08/2025 a un prezzo medio ponderato di $2,1163 e di 284.190 azioni il 26/08/2025 a un prezzo medio ponderato di $2,0808. Dopo la vendita del 25/08 il documento riporta che Reprogrammed deteneva beneficiariamente 38.586.755 azioni, mentre dopo la vendita del 26/08 risultano 38.302.565 azioni.

Il dichiarante specifica che le azioni sono detenute da Reprogrammed Interchange LLC e che Reid Hoffman può essere considerato beneficiario in virtù del controllo condiviso e di un interesse pecuniario indiretto, pur rinunciando a qualsiasi proprietà beneficiaria salvo per la misura del suo interesse pecuniario. Le transazioni sono state firmate il 27/08/2025 da Frank Huang, Manager di Reprogrammed Interchange LLC, e da Reid Hoffman.

Reprogrammed Interchange LLC, entidad vinculada a Reid Hoffman, notificó ventas de acciones ordinarias de Vor Biopharma Inc. (VOR) los días 25 y 26 de agosto de 2025. El informe muestra la venta de 387.346 acciones el 25/08/2025 a un precio medio ponderado de $2.1163, y de 284.190 acciones el 26/08/2025 a un precio medio ponderado de $2.0808. Tras la venta del 25/08 el documento reporta que Reprogrammed poseía beneficiariamente 38.586.755 acciones, y después de la venta del 26/08 se informaron 38.302.565 acciones.

El declarante indica que las acciones están en poder de Reprogrammed Interchange LLC y que Reid Hoffman puede considerarse beneficiario por el control compartido y un interés pecuniario indirecto, aunque renuncia a la condición de propietario beneficiario salvo en la medida de su interés pecuniario. Las operaciones fueron firmadas el 27/08/2025 por Frank Huang, gerente de Reprogrammed Interchange LLC, y por Reid Hoffman.

Reprogrammed Interchange LLCëŠ� Reid Hoffmanê³� ì—°ê´€ë� 당사로서 2025ë…� 8ì›� 25~26ì� Vor Biopharma Inc.(VOR) 보통ì£� 매ë„ë¥� 보고했습니다. 신고서ì—ëŠ� 2025-08-25ì—� 387,346ì£� 매ë„ê°€ 가중í‰ê· ê°€ê²� $2.1163ì—�, 2025-08-26ì—� 284,190ì£� 매ë„ê°€ 가중í‰ê· ê°€ê²� $2.0808ì—� ì´ë£¨ì–´ì¡Œë‹¤ê³  기재ë˜ì–´ 있습니다. 8/25 ë§¤ë„ í›� Reprogrammedê°€ 38,586,755주를 실질ì ìœ¼ë¡� 보유하고 있었ê³�, 8/26 ë§¤ë„ í›„ì—ëŠ� 38,302,565ì£�ë¡� ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

ì‹ ê³ ì¸ì€ 해당 주ì‹ì� Reprogrammed Interchange LLCì—� ì˜í•´ 보유ë˜ê³  있으ë©� Reid Hoffmanì€ ê³µë™ í†µì œ ë°� ê°„ì ‘ì ì¸ 재정ì � ì´í•´ê´€ê³„로 ì¸í•´ 실질ì � 보유ìžë¡œ 간주ë� ìˆ� 있으ë‚�, ìžì‹ ì� 재정ì � ì´í•´ê´€ê³� 범위ë¥� 제외하고ëŠ� 실질ì � 보유ë¥� ë¶€ì¸í•œë‹¤ê³  ë°í˜”습니ë‹�. 거래ëŠ� 2025-08-27ì—� Reprogrammed Interchange LLCì� 매니저 Frank Huangê³� Reid Hoffmanì—� ì˜í•´ 서명ë˜ì—ˆìŠµë‹ˆë‹�.

Reprogrammed Interchange LLC, entité liée à Reid Hoffman, a déclaré des ventes d'actions ordinaires de Vor Biopharma Inc. (VOR) les 25 et 26 août 2025. Le dépôt indique 387 346 actions vendues le 25/08/2025 à un prix moyen pondéré de 2,1163 $, et 284 190 actions vendues le 26/08/2025 à un prix moyen pondéré de 2,0808 $. Après la vente du 25/08, le document rapporte que Reprogrammed détenait à titre bénéficiaire 38 586 755 actions, et après la vente du 26/08 38 302 565 actions ont été déclarées.

Le déclarant précise que les actions sont détenues par Reprogrammed Interchange LLC et que Reid Hoffman peut être réputé bénéficiaire en raison d'un contrôle partagé et d'un intérêt pécuniaire indirect, tout en déclinant la qualité de propriétaire bénéficiaire sauf dans la mesure de son intérêt pécuniaire. Les opérations ont été signées le 27/08/2025 par Frank Huang, Manager de Reprogrammed Interchange LLC, et par Reid Hoffman.

Reprogrammed Interchange LLC, eine mit Reid Hoffman verbundene Einheit, meldete den Verkauf von Stammaktien der Vor Biopharma Inc. (VOR) am 25. und 26. August 2025. Die Einreichung weist 387.346 verkaufte Aktien am 25.08.2025 zu einem gewichteten Durchschnittspreis von $2,1163 sowie 284.190 verkaufte Aktien am 26.08.2025 zu einem gewichteten Durchschnittspreis von $2,0808 aus. Nach dem Verkauf am 25.08. meldete die Einreichung, dass Reprogrammed wirtschaftlich 38.586.755 Aktien hielt; nach dem Verkauf am 26.08. wurden 38.302.565 Aktien angegeben.

Der Einreicher gibt an, dass die Aktien von Reprogrammed Interchange LLC gehalten werden und dass Reid Hoffman aufgrund gemeinsamer Kontrolle und eines indirekten pecuniären Interesses als wirtschaftlicher Eigentümer gelten kann, wobei er das wirtschaftliche Eigentum jedoch mit Ausnahme seines pecuniären Interesses bestreitet. Die Transaktionen wurden am 27.08.2025 von Frank Huang, Manager von Reprogrammed Interchange LLC, und Reid Hoffman unterzeichnet.

Positive
  • Transparent disclosure of sale quantities, weighted average prices, and post-transaction beneficial ownership
  • Clear identification of reporting persons and their relationship to the issuer (Director and 10% owner)
  • Willingness to provide per-trade price breakdowns upon request, improving traceability
Negative
  • Large insider dispositions: combined sale of 667,536 shares over two days may be viewed negatively by some investors
  • Limited context in the filing about the reason for sales or whether they were pursuant to a trading plan

Insights

TL;DR: Substantial insider sales totaling 667,536 shares across two days; disclosure shows weighted average prices and post-sale holdings.

The Form 4 discloses coordinated sales by an affiliate of a director and 10% owner over two trading days. Combined, the reported dispositions total 667,536 shares at weighted average prices of $2.1163 and $2.0808. The filing gives clear post-transaction beneficial ownership figures, which help quantify the remaining stake. For valuation context, an analyst would multiply reported share counts by the sale prices to estimate proceeds, but that calculation is not included in the filing and is not performed here. The disclosure conforms to Section 16 reporting norms and includes the filers offer to provide per-trade price breakdowns upon request.

TL;DR: Filing documents required insider sales and clarifies beneficial ownership and disclaimers; governance disclosure appears complete.

The Form 4 identifies the reporting entity, relationship to the issuer (Director and 10% owner), and provides explanatory footnotes about shared control and disclaimers by Reid Hoffman. The signature block indicates timely execution. The filing notes multiple trades with weighted average prices and offers additional per-trade detail on request, which is good governance practice for transparency. No amendments or 10b5-1 plan box are indicated in the provided content.

Reprogrammed Interchange LLC, entità collegata a Reid Hoffman, ha comunicato la vendita di azioni ordinarie di Vor Biopharma Inc. (VOR) nei giorni 25-26 agosto 2025. La comunicazione indica la vendita di 387.346 azioni il 25/08/2025 a un prezzo medio ponderato di $2,1163 e di 284.190 azioni il 26/08/2025 a un prezzo medio ponderato di $2,0808. Dopo la vendita del 25/08 il documento riporta che Reprogrammed deteneva beneficiariamente 38.586.755 azioni, mentre dopo la vendita del 26/08 risultano 38.302.565 azioni.

Il dichiarante specifica che le azioni sono detenute da Reprogrammed Interchange LLC e che Reid Hoffman può essere considerato beneficiario in virtù del controllo condiviso e di un interesse pecuniario indiretto, pur rinunciando a qualsiasi proprietà beneficiaria salvo per la misura del suo interesse pecuniario. Le transazioni sono state firmate il 27/08/2025 da Frank Huang, Manager di Reprogrammed Interchange LLC, e da Reid Hoffman.

Reprogrammed Interchange LLC, entidad vinculada a Reid Hoffman, notificó ventas de acciones ordinarias de Vor Biopharma Inc. (VOR) los días 25 y 26 de agosto de 2025. El informe muestra la venta de 387.346 acciones el 25/08/2025 a un precio medio ponderado de $2.1163, y de 284.190 acciones el 26/08/2025 a un precio medio ponderado de $2.0808. Tras la venta del 25/08 el documento reporta que Reprogrammed poseía beneficiariamente 38.586.755 acciones, y después de la venta del 26/08 se informaron 38.302.565 acciones.

El declarante indica que las acciones están en poder de Reprogrammed Interchange LLC y que Reid Hoffman puede considerarse beneficiario por el control compartido y un interés pecuniario indirecto, aunque renuncia a la condición de propietario beneficiario salvo en la medida de su interés pecuniario. Las operaciones fueron firmadas el 27/08/2025 por Frank Huang, gerente de Reprogrammed Interchange LLC, y por Reid Hoffman.

Reprogrammed Interchange LLCëŠ� Reid Hoffmanê³� ì—°ê´€ë� 당사로서 2025ë…� 8ì›� 25~26ì� Vor Biopharma Inc.(VOR) 보통ì£� 매ë„ë¥� 보고했습니다. 신고서ì—ëŠ� 2025-08-25ì—� 387,346ì£� 매ë„ê°€ 가중í‰ê· ê°€ê²� $2.1163ì—�, 2025-08-26ì—� 284,190ì£� 매ë„ê°€ 가중í‰ê· ê°€ê²� $2.0808ì—� ì´ë£¨ì–´ì¡Œë‹¤ê³  기재ë˜ì–´ 있습니다. 8/25 ë§¤ë„ í›� Reprogrammedê°€ 38,586,755주를 실질ì ìœ¼ë¡� 보유하고 있었ê³�, 8/26 ë§¤ë„ í›„ì—ëŠ� 38,302,565ì£�ë¡� ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

ì‹ ê³ ì¸ì€ 해당 주ì‹ì� Reprogrammed Interchange LLCì—� ì˜í•´ 보유ë˜ê³  있으ë©� Reid Hoffmanì€ ê³µë™ í†µì œ ë°� ê°„ì ‘ì ì¸ 재정ì � ì´í•´ê´€ê³„로 ì¸í•´ 실질ì � 보유ìžë¡œ 간주ë� ìˆ� 있으ë‚�, ìžì‹ ì� 재정ì � ì´í•´ê´€ê³� 범위ë¥� 제외하고ëŠ� 실질ì � 보유ë¥� ë¶€ì¸í•œë‹¤ê³  ë°í˜”습니ë‹�. 거래ëŠ� 2025-08-27ì—� Reprogrammed Interchange LLCì� 매니저 Frank Huangê³� Reid Hoffmanì—� ì˜í•´ 서명ë˜ì—ˆìŠµë‹ˆë‹�.

Reprogrammed Interchange LLC, entité liée à Reid Hoffman, a déclaré des ventes d'actions ordinaires de Vor Biopharma Inc. (VOR) les 25 et 26 août 2025. Le dépôt indique 387 346 actions vendues le 25/08/2025 à un prix moyen pondéré de 2,1163 $, et 284 190 actions vendues le 26/08/2025 à un prix moyen pondéré de 2,0808 $. Après la vente du 25/08, le document rapporte que Reprogrammed détenait à titre bénéficiaire 38 586 755 actions, et après la vente du 26/08 38 302 565 actions ont été déclarées.

Le déclarant précise que les actions sont détenues par Reprogrammed Interchange LLC et que Reid Hoffman peut être réputé bénéficiaire en raison d'un contrôle partagé et d'un intérêt pécuniaire indirect, tout en déclinant la qualité de propriétaire bénéficiaire sauf dans la mesure de son intérêt pécuniaire. Les opérations ont été signées le 27/08/2025 par Frank Huang, Manager de Reprogrammed Interchange LLC, et par Reid Hoffman.

Reprogrammed Interchange LLC, eine mit Reid Hoffman verbundene Einheit, meldete den Verkauf von Stammaktien der Vor Biopharma Inc. (VOR) am 25. und 26. August 2025. Die Einreichung weist 387.346 verkaufte Aktien am 25.08.2025 zu einem gewichteten Durchschnittspreis von $2,1163 sowie 284.190 verkaufte Aktien am 26.08.2025 zu einem gewichteten Durchschnittspreis von $2,0808 aus. Nach dem Verkauf am 25.08. meldete die Einreichung, dass Reprogrammed wirtschaftlich 38.586.755 Aktien hielt; nach dem Verkauf am 26.08. wurden 38.302.565 Aktien angegeben.

Der Einreicher gibt an, dass die Aktien von Reprogrammed Interchange LLC gehalten werden und dass Reid Hoffman aufgrund gemeinsamer Kontrolle und eines indirekten pecuniären Interesses als wirtschaftlicher Eigentümer gelten kann, wobei er das wirtschaftliche Eigentum jedoch mit Ausnahme seines pecuniären Interesses bestreitet. Die Transaktionen wurden am 27.08.2025 von Frank Huang, Manager von Reprogrammed Interchange LLC, und Reid Hoffman unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/25/2025 S 387,346 D $2.1163(1) 38,586,755(2) D
Common Stock 08/26/2025 S 284,190 D $2.0808(3) 38,302,565(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Reprogrammed Interchange LLC

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Hoffman Reid

(Last) (First) (Middle)
101 MISSION STREET, SUITE 1000

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $2.05 to $2.215. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
3. This transaction was executed in multiple trades at prices ranging from $2.06 to $2.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Frank Huang, Manager of Reprogrammed Interchange LLC 08/27/2025
/s/ Reid Hoffman 08/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Reprogrammed Interchange LLC sell in the VOR Form 4?

The filing reports sales of 387,346 shares on 08/25/2025 and 284,190 shares on 08/26/2025 of Vor Biopharma Inc. common stock.

At what prices were the VOR shares sold according to the Form 4?

The weighted average sale prices reported are $2.1163 for 08/25/2025 and $2.0808 for 08/26/2025, with per-trade ranges disclosed in footnotes.

How many VOR shares did the reporting person beneficially own after the reported sales?

The filing reports 38,586,755 shares after the 08/25 sale and 38,302,565 shares after the 08/26 sale.

Does Reid Hoffman claim ownership of the shares held by Reprogrammed Interchange LLC?

The filing states Reid Hoffman may be deemed a beneficial owner due to shared control and indirect pecuniary interest but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.

Who signed the Form 4 for these VOR transactions and when?

The Form 4 is signed by Frank Huang, Manager of Reprogrammed Interchange LLC and by Reid Hoffman, both dated 08/27/2025.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

260.97M
72.41M
42.84%
43.61%
14.86%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE